Kings Point Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kings Point Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-106	Closed	-$19K	–	375
2015 Q2	$19K	Hold	106	–	–	﹤0.01%	299
2015 Q1	$18K	Hold	106	–	–	﹤0.01%	306
2014 Q4	$17K	Hold	106	–	–	﹤0.01%	295
2014 Q3	$17K	Hold	106	–	–	0.01%	267
2014 Q2	$16K	Buy	+106	New	+$14.7K	﹤0.01%	273
2014 Q1	–	Sell	-109	Closed	-$14K	–	281
2013 Q4	$14K	Buy	+109	New	+$11.3K	﹤0.01%	235

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

WBC

Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Kings Point Capital Management's JAZZ Position: Q3 2015 in Review

Kings Point Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2015, closing a stake of 106 shares — an estimated $19K sold.

Kings Point Capital Management first reported a position in JAZZ in Q4 2013 and held it in 6 quarters. The position peaked at $19K in Q2 2015. 360 funds tracked by Wall St. Rank hold JAZZ as of Q3 2015.

Kings Point Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Kings Point Capital Management sold 106 Jazz Pharmaceuticals shares in Q3 2015, an estimated $19K.
Kings Point Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Kings Point Capital Management's Jazz Pharmaceuticals position peaked at $19K in Q2 2015.
360 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2015.

Based on Kings Point Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.